The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
CD44 is the principal cell surface receptor for hyaluronate
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., & Seed, B. (1990) · Cell · doi:10.1016/0092-8674(90)90694-a · Cited by 2,438
Gene silencing by microRNAs: contributions of translational repression and mRNA decay
Huntzinger, E., & Izaurralde, E. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2936 · Cited by 2,339
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010 · cited 1×
“MicroRNA-34a (miR-34a) is a miRNA regulated by the p53 network at transcriptional level and has been shown to be remarkably downregulated in a variety of cancers [10].”
BackgroundThe microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., DeSano, J. T., Bommer, G. T., Fan, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006816 · Cited by 689
Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., & Zucman-Rossi, J. (2008) · Hepatology · doi:10.1002/hep.22256 · Cited by 684
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
The Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Wang, H., Zhao, Y., Wu, Y., Hu, Y.-L., Nan, K., Nie, G., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.032 · Cited by 603
Self-citationZhang, L., Lu, Z., Zhao, Q., Huang, J., Shen, H., & Zhang, Z. (2011) · Small · doi:10.1002/smll.201001522 · Cited by 590
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
Oh, E. J., Park, K., Kim, K. S., Kim, J., Yang, J.-A., Kong, J.-H., Lee, M. Y., Hoffman, A. S., & Hahn, S. K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.010 · Cited by 540
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy
Choi, K. Y., Yoon, H. Y., Kim, J.-H., Bae, S. M., Park, R.-W., Kang, Y. M., Kim, I.-S., Kwon, I. C., Choi, K., Jeong, S. Y., et al. (2011) · ACS Nano · doi:10.1021/nn202070n · Cited by 399
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugates
Yoo, H. S., Lee, K. H., Oh, J. E., & Park, T. G. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00280-7 · Cited by 374
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
Coley, H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.007 · Cited by 351
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Creixell, M., & Peppas, N. A. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.013 · Cited by 331
Li, L., Yuan, L., Luo, J., Gao, J., Guo, J., & Xie, X. (2013) · Clinical and Experimental Medicine · doi:10.1007/s10238-012-0186-5 · Cited by 314
Doxorubicin-induced apoptosis: Implications in cardiotoxicity
Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002) · Oxygen/Nitrogen Radicals: Cell Injury and Disease · doi:10.1007/978-1-4615-1087-1_13 · Cited by 296
Doxorubicin-induced apoptosis: Implications in cardiotoxicity
Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1015976430790 · Cited by 293
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Novel Hyaluronic Acid-Chitosan Nanoparticles for Ocular Gene Therapy
de la Fuente, M., Seijo, B., & Alonso, M. J. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1077 · Cited by 287
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?
Tong, A. W., & Nemunaitis, J. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.8 · Cited by 250
microRNA: A Master Regulator of Cellular Processes for Bioengineering Systems
Sun, W., Julie Li, Y.-S., Huang, H.-D., Shyy, J. Y.-J., & Chien, S. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105314 · Cited by 236
Parr, C., Watkins, G., & Jiang, W. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.14.5.779 · Cited by 234
Cheng, D., Cao, N., Chen, J., Yu, X., & Shuai, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.057 · Cited by 184
microRNA: Emerging therapeutic targets in acute ischemic diseases
Fasanaro, P., Greco, S., Ivan, M., Capogrossi, M. C., & Martelli, F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.003 · Cited by 174
Targeted Delivery of Doxorubicin by HPMA Copolymer-Hyaluronan Bioconjugates
Luo, Y., Bernshaw, N. J., Lu, Z.-R., Kopecek, J., & Prestwich, G. D. (2002) · Pharmaceutical Research · doi:10.1023/a:1015170907274 · Cited by 173
Development of microRNA-145 for therapeutic application in breast cancer
Kim, S., Oh, J., Shin, J., Lee, K.-D., Sung, K. W., Nam, S. J., & Chun, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.026 · Cited by 138
Park, K., Lee, M., Kim, K. S., & Hahn, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.018 · Cited by 133
Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation
Suh, J. S., Lee, J., Choi, Y., Chong, P. C., & Park, Y. J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.039 · Cited by 119
Hu, Q., Jiang, Q., Jin, X., Shen, J., Wang, K., Li, Y. B., Xu, F., Tang, G., & Li, Z. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.016 · Cited by 116
Targeted therapy against Bcl-2-related proteins in breast cancer cells
Emi, M., Kim, R., Tanabe, K., Uchida, Y., & Toge, T. (2005) · Breast Cancer Research · doi:10.1186/bcr1323 · Cited by 114
Duceppe, N., & Tabrizian, M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.017 · Cited by 109
Christensen, M., Larsen, L. A., Kauppinen, S., & Schratt, G. (2009) · Frontiers in Neural Circuits · doi:10.3389/neuro.04.016.2009 · Cited by 106
Al‐Qadi, S., Alatorre‐Meda, M., Zaghloul, E. M., Taboada, P., & Remuñán‐López, C. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.11.009 · Cited by 86
Suma, T., Miyata, K., Ishii, T., Uchida, S., Uchida, H., Itaka, K., Nishiyama, N., & Kataoka, K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.022 · Cited by 79
A new drug nanocarrier consisting of polyarginine and hyaluronic acid
Oyarzun-Ampuero, F. A., Goycoolea, F. M., Torres, D., & Alonso, M. J. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.04.008 · Cited by 66
Cao, M., Deng, X., Su, S., Zhang, F., Xiao, X., Hu, Q., Fu, Y., Yang, B. B., Wu, Y. F., Sheng, W., et al. (2013) · Nanoscale · doi:10.1039/c3nr04056a · Cited by 62
Self-citationPreparation of polyion complex micelles from poly(ethylene glycol)-block-polyions
Bayó‐Puxán, N., Dufresne, M.-H., Felber, A. E., Castagner, B., & Leroux, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.027 · Cited by 36
Cited by
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Kwak, S.-Y., Lew, T. T. S., Sweeney, C. J., Koman, V. B., Wong, M. H., Bohmert-Tatarev, K., Snell, K. D., Seo, J. S., Chua, N.-H., & Strano, M. S. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0375-4 · Cited by 602
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting
Garg, U., Chauhan, S., Nagaich, U., & Jain, N. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.023 · Cited by 505
Metadata
- Authors
- Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., & Zeng, Y.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 35
- Issue
- 14
- Pages
- 4333-4344
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2010693773
- Cited by
- 511
- References
- 45
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.